Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: Developer, manufacturer, and seller of technologies and products for life science applications, including research, drug discovery, and bioproduction. The company operates globally with a single operating segment.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $20.6 million | $22.0 million | $62.8 million | $69.6 million |
| Gross Profit | $12.0 million | $12.8 million | $35.7 million | $40.8 million |
| Gross Margin | 58.4% | 58.1% | 56.9% | 58.6% |
| Operating Income (Loss) | $0.2 million | $(1.9) million | $(50.3) million | $(6.2) million |
| Net Loss | $(1.2) million | $(4.8) million | $(53.9) million | $(12.4) million |
| Cash and Equivalents | $6.8 million | $4.1 million (Dec 2024) | $6.8 million | $4.6 million (Sep 2024) |
| Total Debt (Current) | $34.0 million | $37.0 million (Dec 2024) | $34.0 million | $37.0 million (Dec 2024) |
| Operating Cash Flow (9M) | $6.8 million | $(0.3) million | $6.8 million | $(0.3) million |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 6.3% in Q3 and 9.7% for the nine months ended September 30, 2025, compared to the prior year. Management attributes this to softening global demand from academic institutions and CROs, as well as the impact of reciprocal tariffs.
- Goodwill Impairment: A non-cash goodwill impairment charge of $48.0 million was recorded in the first quarter of 2025 due to a sustained decrease in stock price, liquidity risks, and macroeconomic conditions. This charge significantly impacted the nine-month net loss.
- Expense Reductions: Operating expenses decreased across all categories (Sales & Marketing, G&A, R&D) primarily due to reduced compensation costs and travel expenses.
- Debt Covenant Waivers: The company failed to meet refinancing milestones and financial covenants as of June 30, 2025. An amendment in August 2025 waived these defaults but increased the interest rate margin (SOFR + 700 bps) and set a hard deadline for refinancing or repayment by December 5, 2025.
Outlook, Risks, and Contingencies
- Going Concern Doubt: The filing explicitly states there is "substantial doubt" about the company's ability to continue as a going concern. Unless the company can refinance its debt or access new capital by December 5, 2025, it may be unable to meet debt obligations and fund operations for the next 12 months.
- Debt Maturity: The Credit Agreement matures on December 22, 2025. The revolving credit facility is capped at $12.65 million, and the company cannot borrow additional funds under current terms.
- Nasdaq Listing Status: The company received notice of non-compliance with Nasdaq's minimum bid price requirement ($1.00). It was transferred to the Nasdaq Capital Market in October 2025, granting an additional 180-day grace period (until March 30, 2026) to regain compliance, potentially via a reverse stock split.
- Internal Controls: Material weaknesses in internal controls over financial reporting (specifically regarding order-to-cash and inventory counts) remain unremediated as of September 30, 2025.
Investor Verification Checklist
- Refinancing Progress: Verify if the company has secured a definitive agreement for refinancing or repayment of the $34 million debt by the December 5, 2025 deadline.
- Liquidity Runway: Assess the sufficiency of the $6.8 million cash balance against upcoming debt service and operating costs given the inability to draw on the revolver.
- Stock Price Recovery: Monitor the stock price to determine if a reverse stock split will be necessary to maintain Nasdaq listing by March 2026.
- Revenue Trends: Evaluate whether the decline in revenue from academic and CRO sectors is stabilizing or accelerating due to tariff impacts.
- Control Remediation: Review updates on the remediation of material weaknesses in internal controls over financial reporting.